Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy
15 juin 2023 11h05 HE
|
Neurona Therapeutics
Promising reduction (>95%) in seizure frequency at the key one-year post treatment endpoint in the first patient to receive NRTX-1001, memory improvements, and seizure-freedom since seven-months...
Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting
24 avr. 2023 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration is well-tolerated with continued seizure reduction of >90% in the first two patients at nine- and five-months post-treatment, respectively Impaired-awareness seizures...
Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference
08 mars 2023 16h01 HE
|
Neurona Therapeutics
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders,...
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
14 févr. 2023 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment, respectively Data & Safety Monitoring Board...
Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting
05 déc. 2022 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration was well-tolerated, with notable seizure reduction reported in early data from the first two patients in Phase I/II clinical trial Additional preclinical data highlight...
Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data
21 nov. 2022 08h00 HE
|
Neurona Therapeutics
Early data from the first two patients treated with NRTX-1001 report a trend toward seizure suppression and that administration of the cell treatment has been well-tolerated thus far Pioneering cell...
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
21 sept. 2022 12h00 HE
|
Neurona Therapeutics
Clinical assessments three-months post-treatment report no serious adverse events and reduced seizure frequency to date in first trial participant Data Safety Monitoring Board clears advancement of...
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy
29 juin 2022 07h00 HE
|
Neurona Therapeutics
Neurona has initiated dosing of a first-ever regenerative human cell therapy candidate in a Phase 1/2 clinical trial for epilepsy Pioneering cell therapy approach could revolutionize the treatment of...
Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting
17 juin 2022 16h55 HE
|
Neurona Therapeutics
Oral presentation will outline design of first ever Phase 1/2 clinical trial of regenerative human cell therapy in epilepsy Presentations will detail single-cell transcriptomic profiling of NRTX-1001...
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy
26 mai 2022 16h00 HE
|
Neurona Therapeutics
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate...